AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03978572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Cycling
Description: Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
Study NCT01424319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan low dose group
Description: Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
Study NCT01424319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan high dose group
Description: Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
Study NCT01424319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atrasentan placebo group
Description: Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
Study NCT00492583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
Study NCT03430336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDSS provides drug-therapy relevant information
Description: External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).
Study NCT03430336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modification of medication
Description: GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
Study NCT01833013 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: live birth date and quality of life assessment
Study NCT02071121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: BIIB061 capsules for oral administration
Study NCT02071121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BIIB061 matching placebo capsules
Study NCT02071121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-BIIB061
Description: Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
Study NCT01161862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-hormonal (insulin and glucagon) artificial pancreas
Description: Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
Study NCT04100265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)
Description: The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.
Study NCT04100265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)
Description: The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
Study NCT01175252 — intervention group
Intervention type: OTHER
Intervention: Database analysis
Description: Review and collect data from database
Study NCT03598556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 180,000IU Vitamin D3 oral emulsion
Study NCT03598556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04073498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
Study NCT03430336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of medication appropriateness
Description: GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.
Study NCT03430336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication plan
Description: GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.
Study NCT03430336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance in medication process
Description: GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
Study NCT04379960 — intervention group
Intervention type: OTHER
Intervention: Peptides
Description: Peptides will be added to PBMCs in in vitro cell culture.
Study NCT00360672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
Study NCT00669513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation
Description: Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
Study NCT04333992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol and remifentanil
Description: intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
Study NCT04333992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane and remifentanil
Description: inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
Study NCT03938636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study NCT02955771 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PDT-Deuteporfin（6 hour)
Description: Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
Study NCT02955771 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PDT-Deuteporfin（9 hour)
Description: Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
Study NCT02955771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenting
Description: The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
Study NCT02955771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: stenting
Description: The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
Study NCT00068484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00068484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT03216070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 50 MG
Description: 50mg of dasatinib orally daily
Study NCT00068484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00068484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03074318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT03074318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Given IV
Study NCT03991468 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Slide Imaging
Description: Scanning of a glass slide to create a digital image that can be viewed on a monitor
Study NCT03991468 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Light Microscopy
Description: Use of traditional light microscopy per institutional standard practice
Study NCT03385434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endorings-2
Description: 292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
Study NCT02428075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCHV visit
Description: Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
Study NCT02177214 — intervention group
Intervention type: PROCEDURE
Intervention: MRI scan
Description: Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
Study NCT03177174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: radiotherapy combined with Chemotherapy Drugs, Cancer
Study NCT00731952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade and Vorinostat
Description: Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
Study NCT00691977 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy followed by prostatectomy
Description: Radiation Therapy
Study NCT00645203 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cefdinir
Description: cefdinir oral suspension, 25 mg/kg once daily for 10 days
Study NCT04616794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Engagement Group
Description: Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.
Study NCT04616794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Group
Description: Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.
Study NCT04616794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Group
Description: Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.
Study NCT04616794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal group
Description: Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
Study NCT02915692 — intervention group
Intervention type: DEVICE
Intervention: ERASE Silver Coated Foley Catheter
Description: Foley catheter from ERASE CAUTI Kit will be administered as required.
Study NCT02915692 — intervention group
Intervention type: DEVICE
Intervention: Comparator Silver Coated Catheter
Description: Foley catheter coated with silver
Study NCT02636738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vela XL thulium laser, laser fiber and accessories.
Description: The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
Study NCT04298749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-P1 or Placebo (dose level 1)
Description: GX-P1 dose level 1 or placebo
Study NCT04298749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-P1 or Placebo (dose level 2)
Description: GX-P1 dose level 2 or placebo
Study NCT04298749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-P1 or Placebo (dose level 3)
Description: GX-P1 dose level 3 or placebo
Study NCT03382327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical planning
Description: Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
Study NCT03365440 — intervention group
Intervention type: DEVICE
Intervention: esoECG-3D catheter
Description: Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
Study NCT01333462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Study NCT01333462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Study NCT01333462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Study NCT03498989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preterm formula milk
Description: A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound.
Study NCT03498989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exclusive breast milk
Description: exclusive breast milk
Study NCT00810251 — intervention group
Intervention type: DEVICE
Intervention: MatrixRIB (FDA Approval # K081623)
Description: MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
Study NCT00763178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose
Study NCT01355497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.
Study NCT01355497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subject will receive matching placebo for the duration of the trial
Study NCT04142944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 with alert
Description: Dexcom G6 CGM device with the predictive hypoglycaemia alert function
Study NCT04142944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6 without alert
Description: Dexcom G6 CGM device without the predictive hypoglycaemia alert function
Study NCT03225651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear cells
Study NCT03225651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological therapy and Rehabilitation
Description: Psychological Therapy and Rehabilitation for autism children around 3 months
Study NCT04157751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Film-coated tablet
Study NCT04157751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Empagliflozin
Description: Film-coated tablet
Study NCT04073498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered by SC injection according to cohort dosing instructions.
Study NCT01929512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201 750/20mg
Description: 750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
Study NCT01929512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR 750mg
Description: Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
Study NCT01929512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
Study NCT01581996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanthanum carbonate
Description: All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
Study NCT00671970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Erlotinib
Description: Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs \& 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
Study NCT03177174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel
Study NCT04663295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™ 670G system
Description: Hybrid closed loop insulin pump with associated CGM and blood glucose meter
Study NCT04242914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous Ketamine, dose 0.5mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
Study NCT04242914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
Study NCT03275064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LNA043
Description: LNA043 intra-articular injection
Study NCT03094494 — intervention group
Intervention type: OTHER
Intervention: none intervention
Description: none intervention
Study NCT01429155 — intervention group
Intervention type: GENETIC
Intervention: Interleukin 28B genotype
Description: Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
Study NCT01456520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vycavert
Description: single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
Study NCT01456520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco
Description: single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
Study NCT03084432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorptiometry
Description: Dual Energy X-ray Absorptiometry done for both studied groups